IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Go back to IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers| (NASDAQ: IDYA) | Delayed: 33.86 +2.63 (8.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.23 | 52 Week High | $ | |||
| Open | $31.84 | 52 Week Low | $ | |||
| Day High | $34.33 | P/E | N/A | |||
| Day Low | $31.81 | EPS | $ | |||
| Volume | 746,823 | |||||
